A systematic review of potential screening biomarkers for active TB disease
- PMID: 34805557
- PMCID: PMC8590066
- DOI: 10.1016/j.jctube.2021.100284
A systematic review of potential screening biomarkers for active TB disease
Abstract
Introduction: The standard TB Four Symptom Screen does not meet the World Health Organization (WHO) ideal screening criteria for having greater than 90% sensitivity to identify active TB disease, regardless of HIV status. To identify novel screening biomarkers for active TB, we performed a systematic review of any cohort or case-control study reporting associations between screening biomarkers and active TB disease.
Methods: We searched PubMed and Embase for articles published before October 10, 2021. We included studies from high or medium tuberculosis burden countries. We excluded articles focusing on C-reactive protein and lipoarabinomannan. For all included biomarkers, we calculated sensitivity, specificity and 95% confidence intervals, and assessed study quality using a tool adapted from the QUADAS-2 risk of bias.
Results: From 8,062 abstracts screened, we included 79 articles. The articles described 302 unique biomarkers, including host antibodies, host proteins, TB antigens, microRNAs, whole blood gene PCRs, and combinations of biomarkers. Of these, 23 biomarkers had sensitivity greater than 90% and specificity greater than 70%, meeting WHO criteria for an ideal screening test. Among the eleven biomarkers described in people living with HIV, only one had a sensitivity greater than 90% and specificity greater than 70% for active TB.
Conclusion: Further evaluation of biomarkers of active TB should be pursued to accelerate identification of TB disease.
Keywords: Screening; Systematic review; Tuberculosis.
© 2021 The Authors. Published by Elsevier Ltd.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Screening tests for active pulmonary tuberculosis in children.Cochrane Database Syst Rev. 2021 Jun 28;6(6):CD013693. doi: 10.1002/14651858.CD013693.pub2. Cochrane Database Syst Rev. 2021. PMID: 34180536 Free PMC article.
-
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD013694. doi: 10.1002/14651858.CD013694.pub2. Cochrane Database Syst Rev. 2021. PMID: 33755189 Free PMC article.
-
Host blood protein biomarkers to screen for tuberculosis disease: a systematic review and meta-analysis.J Clin Microbiol. 2024 Nov 13;62(11):e0078624. doi: 10.1128/jcm.00786-24. Epub 2024 Oct 24. J Clin Microbiol. 2024. PMID: 39445833 Free PMC article.
-
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV.Cochrane Database Syst Rev. 2019 Oct 21;10(10):CD011420. doi: 10.1002/14651858.CD011420.pub3. Cochrane Database Syst Rev. 2019. PMID: 31633805 Free PMC article. Review.
-
Universal screening for SARS-CoV-2 infection: a rapid review.Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718. Cochrane Database Syst Rev. 2020. PMID: 33502003 Free PMC article.
Cited by
-
COVID-19 and Tuberculosis: Mathematical Modeling of Infection Spread Taking into Account Reduced Screening.Diagnostics (Basel). 2024 Mar 26;14(7):698. doi: 10.3390/diagnostics14070698. Diagnostics (Basel). 2024. PMID: 38611611 Free PMC article.
-
Evaluating the expression level of serum Interleukin-2, lipoarabinomannan and circulating MicroRNA-29a as diagnostic biomarkers for pulmonary and extra-pulmonary tuberculosis: a pilot study.Ann Med. 2025 Dec;57(1):2527949. doi: 10.1080/07853890.2025.2527949. Epub 2025 Jul 7. Ann Med. 2025. PMID: 40622143 Free PMC article.
-
Editorial: Exosomes and exosomal miRNAs as biomarkers in infection with Mycobacterium tuberculosis.Front Cell Infect Microbiol. 2023 Jul 26;13:1239739. doi: 10.3389/fcimb.2023.1239739. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37565065 Free PMC article. No abstract available.
-
Significance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection.Front Cell Infect Microbiol. 2024 May 21;14:1398077. doi: 10.3389/fcimb.2024.1398077. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38836056 Free PMC article. Review.
-
Diagnostic biomarkers for active tuberculosis: progress and challenges.EMBO Mol Med. 2022 Dec 7;14(12):e14088. doi: 10.15252/emmm.202114088. Epub 2022 Oct 31. EMBO Mol Med. 2022. PMID: 36314872 Free PMC article. Review.
References
-
- Global tuberculosis report 202Geneva; 2021.
-
- WHO. Systematic screening for active tuberculosis. 2013: 1–146.
-
- van't Hoog A.H., Langendam M., Mitchell E., Cobelens F.G., Sinclair D., Leeflang M.M.G., et al. Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status. Cochrane Database Syst Rev. 2014;2014 doi: 10.1002/14651858.CD010890. - DOI - PMC - PubMed
-
- Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO’s recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV [Internet] World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved; 2018; 5: e515–e523Available from: 10.1016/S2352-3018(18)30137-1. - PubMed
-
- World Health Organization Executive Board. Global strategy and targets for tuberculosis prevention , care and control after 2015, November 2013, pp. 1–23, 2012015; : 1–23.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials